Telmisartan is effective to ameliorate metabolic syndrome in rat model - a preclinical report

• Published in: Diabetes, metabolic syndrome and obesity Vol. 11; pp. 901 - 911
• Main Authors: Cheng, Kai-Chun, Li, Yingxiao, Chang, Wei-Ting, Kuo, Feng Yu, Chen, Zhih-Cherng, Cheng, Juei-Tang
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2018; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Angiotensins; Blood pressure; Cardiovascular agents; Cardiovascular diseases; Diabetes; Diet; Drug dosages; Drug therapy; Fatty acids; Glucose; Glucose metabolism; GSK0660; Hyperglycemia; Hypertension; Insulin; Insulin resistance; Lipids; Liver; Medical research; Metabolic diseases; Metabolic syndrome; Musculoskeletal system; Original Research; Oxidative stress; Patient outcomes; Pharmacy; Phosphates; PPARδ; Prediabetic state; Rodents; Streptozocin; Substance abuse treatment; Telmisartan; United States > US; Japan; Taiwan; metabolic syndrome; GSK0660; diet; telmisartan; PPARδ

Metabolic syndrome (MS) is known to be associated with hypertension, insulin resistance, and dyslipidemia, and it raises the risk for cardiovascular diseases and diabetes mellitus. Telmisartan is used in clinic as an angiotensin II receptor blocker and it is also identified as activating peroxisome...